Search

A tough week for markets as concerns over recession, persistent inflation, and geopolitical tensions grow. Explorer stocks were not spared as they all pulled back with exception of Oracle (ORCL) and micro-cap Kraken Robotics (KRKNF). New restrictions on chip-related sales to China hit semiconductor stocks. An almost $8 billion deal by Brookfield Renewable Partners and uranium producer Cameco to buy nuclear services firm Westinghouse is the latest sign of revival in nuclear power after years of decline. The matchup would create something of a Western nuclear powerhouse, pairing a key nuclear power service provider with the largest publicly traded uranium company and one of the world’s biggest owners of wind and solar projects.

This week we sell two positions and go to Japan for a conservative, high quality play on an overlooked but critical part of the electric vehicle revolution.

A large number of our portfolio stocks are experiencing bullish price action right now. Unless something ugly hits news headlines in the next few days, we’re probably going to enjoy a strong stock market in the first half of July. I hope you’re not sitting on the sidelines!

Though the market has been stagnant of late, its resilience in the face of the DeepSeek surprise, a barrage of tariff news and threats, an uncertain interest-rate climate and ongoing geopolitical strife has actually been impressive. It’s clear stocks want to go up, if they can just get a sufficient catalyst. For now, the best earnings season in three years is propping up the market, and breadth has improved from much of the last two years. With that in mind, today we add a small-cap stock that’s a household name. It was a Covid-era darling that fell severely out of favor the last few years. Now, it’s showing signs of a comeback. I recently recommended the stock to my Cabot Value Investor audience. Now, we add the stock to our Stock of the Week portfolio.

Details inside.

For some time I’ve felt that we should be bumping up the upper end of our market cap range since the market’s evolution, and rising share prices, has made for somewhat slim pickings for high growth names in the under $3 billion market cap range. That is the rough upper end that I’ve been holding to for many years.

Global stock, bond, oil and gold markets continue to bounce around as investors look for trends that signal a re-entry into stocks. Today, I’d like to review facts vs. fiction, in order to give us a little more peace as we live through the stock market correction.

U.S. stock markets have exhibited a high degree of volatility in recent weeks. There are lots of factors contributing to the turmoil, which will ebb and flow, probably for the rest of our lives. So let’s just circle back to why we’re here: We’re here to invest in stocks because over the long term, stocks outperform fixed income investments.

Last Thursday evening, I was a guest at a friend’s regular poker game. It seemed friendly enough – the regulars were average players (like myself), pleasant to spend time with (no jerks), and the evening included a tasty dinner. Also, favorably to me as the newbie, the stakes were modest.

The games were straightforward: 5-card draw, 7-card stud high-low, while a few others included a small field of common cards similar to Texas Hold’em. Betting was reasonable, with limits on both the size and number of raises. So far, so good.

Current Market Outlook


Last week’s action was encouraging, with the major indexes snapping back decently from Monday’s selloff and with many individual growth stocks either acting resiliently and/or reacting well to earnings. That said, three up days (Tuesday-Thursday last week) are not enough to reverse the prior meltdown—right now, all major indexes are below their 50-day moving averages and, generally speaking, the overall intermediate-term trend is neutral-to-negative. We’re not advising you to hole up in your bunker, but the onus is on the bulls to prove that the tariff-induced decline was a shakeout; until then, it’s best to remain cautious by holding some cash, keeping new buys small and making sure your losers and laggards don’t slip much further.

Going along with the action in growth stocks, this week’s list is chock-full of recent earnings winners. Our Top Pick is TransDigm (TDG), a solid 20%-ish grower in the aerospace field that gapped on earnings and is set to pay a huge one-time dividend.

Stock Name	Price	Buy Range	Loss Limit
Carvana (CVNA)	82.90	75-78.5	64-66
Insulet (PODD)	175.69	144-147	128-131
Lattice Semi (LSCC)	23.92	17.5-18.5	15.5-16.2
Martin Marietta Materials (MLM)	261.52	243-250	218-222
Medpace (MEDP)	76.28	75.5-78.5	67.5-69.5
Roku, Inc. (ROKU)	150.46	124-130	107-110
Shake Shack (SHAK)	92.08	85-88	75-77
SolarEdge Technologies Inc. (SEDG)	124.37	80-84	70-72
TransDigm (TDG)	599.41	525-545	475-485
Wingstop (WING)	121.52	95-98	88-90

I’m plucking my Bank of America (BAC) stock review out of the Growth Portfolio section, and putting it right here in the editorial section of the weekly update. That’s because good news affecting BAC will also affect virtually all bank stocks.

“Founded in 1937, Baltimore-based T. Rowe Price Group, Inc. (TROW – yield 2.50%) is a global investment management organization with $520.9 billion in assets under management as of June 30, 2011. The organization provides a broad array of mutual funds, subadvisory services and separate account management for individual...

After surging to new highs in mid-March, today’s recommendation entered into a tight consolidation pattern—and today it’s still in that pattern! While the broad market has pulled back, this stock has held up strongly, which is a very good sign.

The market’s rebound continues and our stocks, as a whole, continue to perform well. Someday, however, a correction will begin and it will pay to be alert—and to react—when it does.

In the meantime, I will keep recommending the best stocks, a system that has worked quite well in recent weeks. This week, we continue to diversify with a recommendation of a marijuana stock, a group that went through a two-plus year correction and in the process got relatively cheap.



As for the rest of the portfolio, it’s acting well and thus the only change today is a downgrade of one stock from buy to hold.



Full details in the issue.

A year ago, I recommended a cloud software stock to my subscribers that’s up 60% since. Here’s what it is, and what it does.

Crista gives an update on the Section 232 investigation into the steel industry and describes what a normal stock market correction look like and how you should handle it. One rating change.

We enter the last few weeks of the year with plenty of momentum, and this week’s macro data-heavy slate (CPI and PPI reports, the latest Fed announcement) can only do so much damage to our portfolio on the heels of a very strong couple months. Nearly half our holdings – 10! – are trading at 52-week or all-time highs as of this writing. So today, we take another big swing on a mid-cap biotech newly recommended by Carl Delfeld in his Cabot Explorer advisory.

A quick note: we have several stocks that are near our stops, or broke below them last week as the market quickly fell 10% following the tariff announcements. For now, I am going to give these trades a bit more time, though if conditions worsen again, we will be exiting these trades very quickly.

It was a historic week for the market, and not for any positive reasons as the S&P 500 fell 9.1%, the Dow lost 7.9% and the Nasdaq declined by 10%. Perhaps the weekend gave traders a bit of time to better digest the tariff news and the market will stabilize this week after an up-and-down Monday (futures are up big on Tuesday, but that can change quickly in these tariff times). It’s also possible that the uncertainty is just too much for traders to digest.

Today’s recommendation is a steel stock! It’s a sector that nobody is excited about, but the value proposition is great, and the stock has just blasted off following an excellent earnings report.

In choosing today’s recommendation, I returned to a sector that was white-hot a few years ago, bringing big profits to investors who got out before the sector collapsed. But now the sector is back in favor and my selection is the leading Chinese stock in the industry.

A year from now we could be in a raging bull market or bounding toward a recession. Interest rates could be high or much lower. And we have to see what will happen with these wars and who will be elected president in November. Nobody knows the answers to these questions.

But a year from now there is at least one thing we can bank on: The population is already older than ever before in history and will continue to get still older at warp speed. Between 2011 and 2029, about 76 million boomers born in the U.S. between 1946 and 1964 will turn 65. That’s about 3.6 million per year. There will be tens of millions more older people running around in the years ahead.

The inescapable fact about older people is that they spend much more than any other segment of the population on healthcare. That’s just how we’re built. Boomers control about 70% of this nation’s wealth and the aging population has enormous implications for businesses and markets.

Certain healthcare companies and stocks are positioned ahead of a megatrend and a massive wave of spending. In this issue, I highlight two “BUY”-rated portfolio healthcare stocks. If you don’t own them already, they are well worth considering.

The market is melting down with no end in sight. The question is, does this more closely resemble the July/August carry trade/weak jobs report selling of last year, when the major indexes fell an almost identical amount to what they have in the past three weeks? Or are we hurtling toward the end of the 28-month bull market? We may know the answer soon, as the all-important February inflation prints are released later this week.

In the meantime, we’re playing plenty of defense in today’s issue, selling out of six of our positions that have completely broken down, and adding shares of a low-risk gold miner that’s been a favorite of Cabot Explorer Chief Analyst Carl Delfeld for some time.

Details inside.